GlassScriptPhysician profile
Maqbool Ahmed
NPI 1023022118
$60,751.86
in general payments reported to CMS, 2019-2025
53 companies · $3,337 in 2025
The $3,337 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $5,079 · 2021: $6,391 · 2022: $26K · 2023: $8,492 · 2024: $11K · 2025: $3,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $7,471 · Consulting Fee: $3,455 · Travel and Lodging: $748 · Education: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,536.00 |
| Food and Beverage | $7,470.65 |
| Consulting Fee | $3,455.00 |
| Travel and Lodging | $747.56 |
| Education | $563.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $39,480.01 | 2019-2025 | Opdivo, Opdualag, Breyanzi |
| Pfizer INC. | $5,166.02 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,549.34 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Taiho Oncology, INC. | $2,219.72 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,511.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,120.65 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $808.35 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Regeneron Healthcare Solutions, INC. | $690.38 | 2021-2025 | Libtayo |
| Daiichi Sankyo INC. | $602.03 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $524.33 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Seagen INC. | $523.75 | 2020-2025 | Adcetris, Padcev, Tukysa |
| Genzyme Corporation | $474.81 | 2020-2025 | |
| Abbvie INC. | $424.50 | 2023-2025 | Venclexta |
| Amgen INC. | $349.72 | 2019-2023 | Kyprolis, Xgeva, Vectibix |
| Genentech USA, INC. | $310.94 | 2019-2025 | Tecentriq, Polivy, Perjeta |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $248.23 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $241.26 | 2019-2024 | Xtandi, Xospata |
| Beigene USA, INC. | $219.91 | 2020-2024 | Brukinsa |
| Pharmaessentia USA Corporation | $178.58 | 2023-2025 | Besremi |
| Jazz Pharmaceuticals INC. | $174.74 | 2021-2025 | |
| Lilly USA, LLC | $166.21 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Kite Pharma, INC. | $131.72 | 2021-2023 | Yescarta |
| Emd Serono, INC. | $120.66 | 2019-2025 | |
| Incyte Corporation | $113.94 | 2023-2024 | Monjuvi, Jakafi, Pemazyre |
| Boston Scientific Corporation | $104.43 | 2023 | Therasphere Administration Set |
| Aadi Bioscience, INC. | $99.00 | 2023 | Fyarro |
| Sanofi-Aventis U.S. LLC | $90.95 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.80 | 2019-2023 | Gilotrif |
| Glaxosmithkline, LLC. | $85.33 | 2021-2025 | Ojjaara |
| Ipsen Biopharmaceuticals, INC | $81.80 | 2019-2024 | Onivyde, Tazverik |
| Takeda Pharmaceuticals U.S.A., INC. | $76.01 | 2019-2025 | Iclusig, Fruzaqla |
| Teva Pharmaceuticals USA, INC. | $66.79 | 2022 | |
| Eisai INC. | $65.51 | 2020-2021 | |
| Tempus Ai, INC | $61.29 | 2024-2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $61.06 | 2023-2024 | Krazati |
| Adaptive Biotechnologies Corporation | $58.87 | 2024-2025 | Clonoseq |
| Coherus Oncology, INC. | $56.33 | 2020-2022 | |
| Servier Pharmaceuticals LLC | $43.32 | 2021-2023 | |
| Sobi, INC | $41.80 | 2022-2023 | |
| Kyowa Kirin, INC. | $36.35 | 2022 | |
| Array Biopharma INC | $34.00 | 2019-2025 | Mektovi, Tukysa, Lorbrena |
| Iovance Biotherapeutics, INC. | $29.19 | 2025 | Amtagvi |
| Beone Medicines USA, INC. | $28.03 | 2025 | Brukinsa |
| Geron Corporation | $26.88 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $25.86 | 2024 | Ultomiris |
| Adc Therapeutics America, INC. | $24.24 | 2025 | |
| Sun Pharmaceutical Industries INC. | $21.25 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $17.50 | 2023 | Imbruvica |
| Exelixis INC. | $16.93 | 2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $16.21 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.42 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.82 | 2020 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maqbool Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.